key: cord-0269231-dvxwdsip
authors: Parveen, Sadiya; Lun, Shichun; Urbanowski, Michael E.; Cardin, Mitchell; Murphy, John R.; Bishai, William R.
title: Effective host-directed therapy for tuberculosis by targeted depletion of myeloid-derived suppressor cells using a diphtheria toxin-based fusion protein
date: 2020-12-10
journal: bioRxiv
DOI: 10.1101/2020.12.10.420224
sha: 49288d5885c630e5e00916850805e016b66f0aa8
doc_id: 269231
cord_uid: dvxwdsip

Myeloid-derived suppressor cells (MDSCs) are present in elevated numbers in TB patients and have been found to be permissive for Mycobacterium tuberculosis (Mtb) proliferation. To determine whether depletion of MDSCs may improve host control of TB, we used a novel diphtheria toxin-based fusion protein known as DABIL-4 that targets and depletes IL-4-receptor positive cells. We show that DABIL-4 depletes both PMN-MDSCs and M-MDSC in the mouse TB model, and that it reduces the lung bacillary burden of Mtb. These results indicate that MDSC-depleting therapies targeting the IL4 receptor are beneficial in TB and offer an avenue towards host-directed TB therapy.

Mycobacterium tuberculosis (Mtb) is second only to COVID-19 in annual global mortality and 50 caused the death of 1.7 million individuals in 2018 alone worldwide [1] . The treatment of TB is 51 complicated by prolonged treatment time, patient compliance, drug-related toxicities, and the 52 emergence of multi-(MDR) and extremely-drug resistance (XDR) strains. Thus, there is an urgent 53 need to develop novel therapeutic approaches against Mtb. Host-directed therapies (HDTs) have the 54 potential to reduce TB associated tissue damage and enhance host-mounted immunity, and they are 55 insensitive to the antibiotic resistant state of the pathogen. In light of these attractive qualities, 56 HDTs have been studied more intensively as an approach to adjunctive TB chemotherapy [2] [3] [4] [5] . Diphtheria toxin-based fusion proteins have been used for targeted, selective cell depletion in 76 animal models and in humans [18] . Owing to the enzymatic killing mechanism of diphtheria toxin, these recombinant proteins kill cells at the picomolar level [19] ; they also have short serum half-78 lives of only 1-2 hours [20] . Therefore, when given systemically they lead to a transient depletion 79 of cells which express the highest levels of the targeted receptor. We recently reported the 80 development of a diphtheria toxin based fusion protein s-DAB1-389-mIL-4 (referred to as DABIL-4 81 hereafter) which showed an IC50 of 2 nM against 4T1, a murine breast adenocarcinoma cell line. 82 We demonstrated that DABIL-4 targets and depletes IL-4R + murine breast cancer cells, as well as 83 tumor-associated MDSCs in a murine 4T1 adenocarcinoma model resulting in reductions of tumor 84 growth and metastases [21] . Given its potency and immunotherapeutic role in cancer, we sought to 85 determine whether DABIL-4-mediated MDSC depletion may play a beneficial role during 86 tuberculosis. In the present study, we evaluated DABIL-4 in the murine model of TB and found that 87 it selectively depletes IL-4R + MDSCs and macrophages in both the lung and spleen and that this 88 was accompanied by a concomitant reduction in the burden of Mtb in the lungs. 91 As shown in Fig 1A, DABIL-4 is a fusion protein toxin which consists of the diphtheria toxin 92 catalytic and translocation domains genetically fused to murine IL-4 (mIL-4). A related diphtheria 93 toxin fusion protein in which IL-2 serves as the targeting domain (DABIL-2) was FDA approved as 94 the drug denileukin diftitox, and it has been shown to have immunotherapeutic effects via depletion 95 of IL-2 receptor (CD25 + )-bearing Treg cells [19, 20, 22] . Prior to evaluating the potential 96 therapeutic effect of DABIL-4 in a murine model of tuberculosis, we assessed the safety and 97 tolerability of the drug in uninfected 129S2 mice. We administered three different doses of the 98 fusion toxin (2.5, 5 and 10 µg / mouse / day) intraperitoneally to mice. After 21 days, mice treated 99 with 5 and 10 µg of DABIL-4 daily showed significant weight loss in a dose-dependent fashion. In 100 contrast mice treated with 2.5 µg daily and the vehicle-control group did not demonstrate weight 101 loss (Fig 1B) . Despite early weight loss, mice receiving 5 or 10 µg daily began to gain weight such 102 that by day 21 they were almost at control levels. Importantly, despite the heavy dosing regimen 103 none of the mice died (data not shown). On day 21, the mice were sacrificed and spleen cells were 104 characterized by flow cytometry. As shown in Fig. 1C , we observed a dose dependent reduction of 105 IL-4R + macrophages in mice that were treated with daily DABIL-4; at the highest dose of 10 µg 106 daily IL-4R + macrophages were depleted by 3.5-fold. These results indicate that DABIL-4 107 administration is reasonably well tolerated and effectively depletes IL-4R + macrophages in vivo. 109 In contrast to wild-type mice, the C3HeB/FeJ ("Kramnik") mouse strain is known to develop 110 necrotic granulomatous lesions following Mtb infection similar to the pathology observed in human 111 TB patients [23] , and they also display elevated levels of MDSCs [13] . To evaluate the potential 112 therapeutic efficacy of DABIL-4, we infected C3HeB/FeJ mice by the aerosol route and treated 113 them with 10 µg DABIL-4 every third day starting on day 3 post-infection ( Fig. 2A) . The day 1 114 Mtb implantation in the lungs was 1.93 ± 0.14 log units (Fig 2B) . After 21 days, mice from both the 115 treated and untreated groups were sacrificed and lungs were collected. The DABIL-4 treated group 116 had a quantitative lung bacterial burden that was 0.35 log units lower than that of the vehicle-117 treated control (p < 0.018) (Fig 2C) . These data show that DABIL-4 monotherapy reduces Mtb 118 proliferation in the lungs of infected mice. and S1B). Interestingly, despite an overall increase in myeloid cell abundance in the lungs, the 128 population of IL-4R + myeloid cells in lungs was reduced by 27% (p < 0.05) (Fig 3A) , the 129 observation is consistent with our breast cancer study [21] . We then characterized the impact of 130 DABIL-4 administration specifically on MDSCs, a cell population known to drive 131 immunosuppression in the granuloma. In DABIL-4 treated mice, there was a 36% reduction (p < 132 0.01) in the total MDSC population in lungs (Fig 3B) . We also evaluated the impact on two distinct (Fig 3C and 3D) . Interestingly, despite DABIL-4 depletion therapy, we saw a small (Fig S2) . 153 In order to investigate whether DABIL-4 selectively targets and depletes only M2-like 154 macrophages, we isolated monocytes from the bone-marrow of healthy, uninfected mice and 155 differentiated these cells into macrophages in presence of L929-conditioned media. We polarized 156 these cells into M1-and M2-like macrophages, and then treated these populations with 4 nM 157 DABIL-4 for 48 hours and scored their viability as described in the Materials and Methods section. 158 We observed a significant decline in the viability of the DABIL-4 treated M2-macrophages (anti-159 inflammatory), whereas pro-inflammatory M1-like macrophages which do not express significant 160 levels of IL-4R positivity showed no loss of viability and actually expanded moderately (Fig 4B) . 161 Based on these results we concluded that DABIL-4 selectively targets and depletes M2-like 162 macrophages. 164 In addition to myeloid cells, CD4 + T lymphocytes also are known to be key players in the The results reported here are consistent with earlier results using non-specific MDSC depletion 219 strategies in the mouse TB model. In an earlier report, our group investigated the activity of 220 tasquinimod, a quinoline-3-carboxamide analog that suppresses the local recruitment and function 221 of MDSCs thorough its interaction with S100A9 [37] , in Mtb-infected mice. We found that The protein concentration was then estimated and aliquots were stored at -80°C. 262 We procured 129S2 mice from Charles River Laboratories (Wilmington, Massachusetts) and 263 aerosol infected using M. tuberculosis H37Rv as previously described. All the protocols were of CD11b + population. Statistical significance between the groups was assessed by two-tailed 341 unpaired student t-test considering an unequal distribution. *p < 0.05, **p < 0.01, ***P < 0.001. Methods. All values are expressed as Mean ± SD. Statistical significance between the groups was 547 assessed by two-tailed unpaired student t-test considering an unequal distribution. *p < 0.05, **p < 548 0.01. 

Global tuberculosis report 2020

Tuberculosis: progress and advances in development of 392 new drugs, treatment regimens, and host-directed therapies

Host-directed therapies for 395 bacterial and viral infections

Du Plessis N. Therapeutic host-directed strategies to improve outcome in 397 tuberculosis

Host-Pathogen Interaction as a Novel Target for Host-Directed 399 Therapies in Tuberculosis

Phenotypically resembling myeloid derived 401 suppressor cells are increased in children with HIV and exposed/infected with Mycobacterium 402 tuberculosis

Gr-1dimCD11b+ immature myeloid-derived 404 suppressor cells but not neutrophils are markers of lethal tuberculosis infection in mice

Granulocytic myeloid derived suppressor cells 407 expansion during active pulmonary tuberculosis is associated with high nitric oxide plasma level

A myeloid cell population induced by Freund 410 adjuvant suppresses T-cell-mediated antitumor immunity

Suppression of BCG cell wall-induced delayed-type hypersensitivity 413 by BCG pre-treatment. II. Induction of suppressor T cells by heat-killed BCG injection

Inhibition of in vitro cytotoxic responses by BCG-416 induced macrophage-like suppressor cells. II. Suppression occurs at the level of a "helper" T 417 cell

Inhibition of Fatty Acid Oxidation 419

Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances 420 Cancer Therapies

Lung-residing myeloid-derived suppressors 422 display dual functionality in murine pulmonary tuberculosis

Human Monocytic Suppressive Cells Promote Replication 425 of Mycobacterium tuberculosis and Alter Stability of in vitro Generated Granulomas

Targeting of IL-4 and IL-13 receptors for cancer 428 therapy

Myeloid-Derived Suppressor Cells 430 in Bacterial Infections

Aptamer-mediated 432 blockade of IL4Ralpha triggers apoptosis of MDSCs and limits tumor progression

Corynebacterium diphtheriae: Diphtheria Toxin, the tox

Its Regulation by Fe2(+) Activation of apo-DtxR

Second-generation IL-2 receptor-targeted diphtheria 437 fusion toxin exhibits antitumor activity and synergy with anti-PD-1 in melanoma. Proceedings of 438 the National Academy of Sciences of the United States of

Denileukin diftitox: a novel immunotoxin

IL-4 receptor targeting as an effective 442 immunotherapy against triple-negative breast cancer

Suppressor Cell-Depleting Immunotherapy With 444

Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis

Ipr1 gene mediates innate immunity to tuberculosis

IL4Ralpha+ myeloid-derived suppressor cell 449 expansion in cancer patients

Tumors induce a subset of inflammatory monocytes 451 with immunosuppressive activity on CD8+ T cells

Alveolar Macrophages Provide an Early

Mycobacterium tuberculosis Niche and Initiate Dissemination

Regulation of interleukin-4 457 receptors on murine myeloid progenitor cells by interleukin-6

CD4+ T cells contain early 459 extrapulmonary tuberculosis (TB) dissemination and rapid TB progression and sustain 460 multieffector functions of CD8+ T and CD3-lymphocytes: mechanisms of CD4+ T cell immunity

CD8+ T cells from patients with tuberculosis is related to the presence of pulmonary cavities

Filarial infection modulates the 466 immune response to Mycobacterium tuberculosis through expansion of CD4+ IL-4 memory T 467 cells

Recent advances with Treg depleting 469 fusion protein toxins for cancer immunotherapy

Denileukin diftitox: a concise clinical review. Expert Review of 471

Interleukin 4 473 receptor targeted cytotoxicity: genetic construction and in vivo immunosuppressive activity of a 474 diphtheria toxin-related murine interleukin 4 fusion protein

Mycobacterium tuberculosis Infection-Driven Foamy Macrophages 477 and Their Implications in Tuberculosis Control as Targets for Host-Directed Therapy

Myeloid-derived suppressor cells: linking inflammation and 480 cancer

Targeting Regulatory Myeloid Cells in Tuberculosis

Neutrophils and the S100A9 protein critically 484 regulate granuloma formation

Pharmacologic Exhaustion of Suppressor Cells with 486

Tasquinimod Enhances Bacterial Clearance during Tuberculosis

Mechanism of all-489 trans retinoic acid effect on tumor-associated myeloid-derived suppressor cells

Myeloid derived suppressor cells-An 492 overview of combat strategies to increase immunotherapy efficacy

IL-4 depletion enhances host resistance and 495 passive IgA protection against tuberculosis infection in BALB/c mice

The IL-13/IL-4Ralpha axis is involved in 498 tuberculosis-associated pathology

 383 We gratefully acknowledge the support of NIH grants AI 130595 and AI 1522688, Tedco awards 384